Evelo Biosciences, Inc. EVLO
Set alert
0.00 USD 0.00 0.00%
At close · Oct 29
0.0005 Day range 0.0005
0.0001 52-week range 0.0005
- YTD
- -80.00%
- 1 year
- -80.00%
- Open
- 0.0005
- Prev close
- 0.0001
- Mkt cap
- 1.90K
- Vol
- 133
- Avg vol
- 2.65K
- EPS
- -3.14
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0005
- High
- 0.0005
- Forward P/E
- -0.03
- Beta
- 1.89
- Short ratio
- 0.12
- Inst. own
- 83.03%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 26, 2024
- 50-d avg
- 0.26256
- 200-d avg
- 3.43
- 1y target
- 10.00
Key statistics
- Market cap
- 1.11M
- Enterprise value
- 17.71M
- Trailing P/E
- 0.00
- Forward P/E
- -0.03
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -15.64
- Beta
- 1.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -43.31M
- Total cash
- 17.26M
- Total debt
- 33.95M
- Return on equity
- 0.00%
- Shares outstanding
- 18.98M
- Short % of float
- 2.22%
- 50-day average
- 0.26256
- 200-day average
- 3.43
Analyst view
Consensus: hold
Hold
Price target (mean) 10.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 26, 2024
Expected Dec 26, 2024. Consensus EPS estimate -0.97.
Financials — quick view
EVLO Revenue — quarterly 0
EVLO Net income — quarterly -12.36M
EVLO EPS — quarterly -0.71
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 26, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 1, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -1.34 | -0.66 | +0.68 | +50.75% |
| Aug 14, 2023 | Jun 1, 2023 | -4.33 | -3.55 | +0.78 | +18.01% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 17, 2023 | TD Cowen | down | Outperform | Market Perform |
| Jul 25, 2023 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Evelo Biosciences, Inc.
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- evelobio.com
News
- Stock Traders Buy Large Volume of Evelo Biosciences Put Options (NASDAQ:EVLO)
- Head to Head Review: Evelo Biosciences (NASDAQ:EVLO) vs. Silverback Therapeutics (NASDAQ:SBTX)
- Evelo Biosciences Sees Unusually High Options Volume (NASDAQ:EVLO)
- Stock Traders Buy High Volume of Evelo Biosciences Put Options (NASDAQ:EVLO)
- Evelo Biosciences (NASDAQ:EVLO) vs. Vincerx Pharma (NASDAQ:VINC) Financial Analysis
- Evelo Biosciences Sees Unusually High Options Volume (NASDAQ:EVLO)
- Analyzing Evelo Biosciences (NASDAQ:EVLO) & Antibe Therapeutics (OTCMKTS:ATBPD)
- EVLO to Provide Dominion Energy With Safety Enhanced Energy Storage Systems
- Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
Your note
Sign in to keep a note on EVLO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BODMER MARK | Officer | Sale | Nov 7, 2023 | 25,732 |
| CARRIERE STEPHEN J | Officer | Sale | Jan 22, 2023 | 203 |
| DARZI LORD ARA | Director | Purchase | May 26, 2022 | 342,465 |
| EPSTEIN DAVID R | Director | Conversion of Exercise of derivative security | Jun 29, 2022 | 93,932 |
| FLAGSHIP VENTURES | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 26, 2022 | 0 |
| GILL BALKRISHAN | Chief Executive Officer | Sale | Nov 7, 2023 | 17,758 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Flagship Pioneering Inc. | 13.39% | 2,521,369 | 8.19M | Jun 29, 2023 |
| Michigan (State Of) Teachers Retirement System | 1.08% | 203,536 | 661.49K | Jun 29, 2023 |
| Credit Suisse Ag/ | 0.96% | 180,520 | 586.69K | Jun 29, 2023 |
| Vanguard Group Inc | 0.83% | 155,896 | 506.66K | Jun 29, 2023 |
| Harbourvest Partners, LLC | 0.81% | 153,175 | 497.82K | Jun 29, 2023 |
| FMR, LLC | 0.67% | 126,425 | 410.88K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.56% | 104,548 | 339.78K | Jun 29, 2023 |
| iShares NASDAQ Biotechnology ETF | 0.35% | 66,186 | 437.49K | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 0.26% | 48,600 | 157.95K | Jun 29, 2023 |
| Fidelity Growth Company K6 Fund | 0.16% | 30,211 | 82.48K | May 30, 2023 |
| Variable Insurance Products Fund-Growth Portfolio | 0.12% | 23,345 | 154.31K | Aug 30, 2023 |
| Fidelity Capital Appreciation Fund | 0.10% | 18,970 | 198.62K | Jul 30, 2023 |